Ellipta Shows Superior Rates of Correct Patient Use Compared with Device Combos
A new study has found that patients with chronic obstructive pulmonary disease (COPD) better manage proper inhaler use with 1 branded single-use device than others.
A new study has found that patients with chronic obstructive pulmonary disease (COPD) better manage proper inhaler use with 1 branded single-use device than others.
Triple-therapy single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Ellipta) showed superior rates of correct patient use and reduced health care provider instruction in a multicenter, single-visit, randomized, open-label, crossover study that compared the GlaxoSmithKline (GSK)-manufactured device to 3 of its market competitors.
The study, funded by GSK, was presented at the 2018 American Thoracic Society (ATS) International Conference in San Diego, CA. The compared therapies included fluticasone/salmeterol (Diskus), tiotropium (HandiHaler), and budersonide/formoterol (Turbuhaler).
Click to continue reading on MD Magazine.
